Brokerages expect Marker Therapeutics Inc (NASDAQ:MRKR) to announce ($0.21) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Marker Therapeutics’ earnings. Marker Therapeutics reported earnings per share of ($0.25) in the same quarter last year, which would suggest a positive year-over-year growth rate of 16%. The company is expected to issue its next earnings report on Friday, March 22nd.
On average, analysts expect that Marker Therapeutics will report full-year earnings of ($1.13) per share for the current year. For the next fiscal year, analysts anticipate that the business will report earnings of ($0.61) per share. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side analysts that follow Marker Therapeutics.
Marker Therapeutics (NASDAQ:MRKR) last announced its quarterly earnings data on Tuesday, November 13th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.12.
Several equities research analysts have issued reports on MRKR shares. Piper Jaffray Companies raised Marker Therapeutics from a “neutral” rating to an “overweight” rating in a report on Monday, December 3rd. ValuEngine upgraded Marker Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, January 5th. Nomura assumed coverage on Marker Therapeutics in a research report on Wednesday, November 21st. They set a “buy” rating and a $16.00 target price on the stock. Finally, Zacks Investment Research upgraded Marker Therapeutics from a “hold” rating to a “buy” rating and set a $4.75 target price on the stock in a research report on Tuesday, December 25th.
Marker Therapeutics stock traded down $0.44 during trading hours on Thursday, reaching $5.78. 8,828 shares of the company’s stock traded hands, compared to its average volume of 393,750. Marker Therapeutics has a fifty-two week low of $2.58 and a fifty-two week high of $13.55. The company has a market cap of $301.71 million, a PE ratio of -5.00 and a beta of 0.09.
A hedge fund recently bought a new stake in Marker Therapeutics stock. Neville Rodie & Shaw Inc. purchased a new position in Marker Therapeutics Inc (NASDAQ:MRKR) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 30,101 shares of the company’s stock, valued at approximately $167,000. Neville Rodie & Shaw Inc. owned approximately 0.07% of Marker Therapeutics as of its most recent SEC filing. Institutional investors own 2.89% of the company’s stock.
About Marker Therapeutics
Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its cell therapy technology is based on the tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets.
Featured Article: Cost of Capital
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Marker Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marker Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.